Can you take Azathioprine with Thymoglobulin?

azaTHIOprine has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia. Therapy with azathioprine should be administered cautiously in patients with bone marrow depression. Hematological toxicities are dose related. Caution and routine monitoring of blood counts and platelets is recommended. Patients should report any unusual bleeding or bruising.

The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.

The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Immunodeficiency.

The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.

azaTHIOprine has a major potential interaction with Infection.

Serious infections, including reactivation of latent infections have been reported with the use of azathioprine. Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine. A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended. Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.

The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Infection.

The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.

azaTHIOprine has a moderate potential interaction with Liver Disease.

Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP). Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease. Therapy with azathioprine should be administered cautiously in patients with liver disease. Monitoring liver function is recommended in these patients.

azaTHIOprine has a major potential interaction with Renal Dysfunction.

Azathioprine may accumulate in patients with impaired renal function. Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.

The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Vaccination.

Patients recently treated with anti-thymocyte globulin [rabbit] should not receive immunizations with live viral vaccines.